Staidson Biopharmaceuticals Hits Day Low at CNY 20.27 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. has experienced significant volatility today, with the stock hitting an intraday low of CNY 20.27, reflecting a decline of 6.81% on June 11, 2026. This performance stands in stark contrast to the China Shanghai Composite, which saw a modest decrease of 0.16% on the same day. Over the past week, Staidson's stock has dropped by 16.92%, and its one-month performance shows a substantial decline of 29.68%. Year-to-date, the stock has fallen by 25.4%, while its one-year performance reveals a notable decrease of 34.8%. Despite a strong performance over the last three and five years, with returns of 92.63% and 90.47% respectively, the recent trends indicate a challenging environment for the company. Key financial metrics highlight concerns, including a negative net worth and a low return on capital employed (ROCE) of 0%. The company has reported losses for six consecutive quarters, with net sales declining by 25.81% in the latest quarter. As Staidson navigates these challenges, its market position remains under scrutiny within the pharmaceuticals and biotechnology sector.